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The uncoupling proteins (UCPs) are mitochondrial
carriers that modulate the energetic efficiency and,
as a result, can lower superoxide levels. Here, we
describe the discovery of a small-molecule inhibitor
of the UCPs. Screening of potential UCP1 regulators
led to the identification of chromane derivatives that
inhibit its proton conductance. Members of the UCP
family can act as a defense against oxidative stress
and, thus, UCP2 plays a protective role in tumor cells.
High UCP2 levels have been associated with chemo-
resistance. We demonstrate that chromanes also
inhibit UCP2 and, in HT-29 human carcinoma cells,
cause oxidative stress. The chromane derivatives
can act synergistically with chemotherapeutic
agents; for instance, they increase the toxicity of
arsenic trioxide in HT-29 cells. These findings open
a promising line in the development of novel anti-
cancer agents.
INTRODUCTION
The uncoupling proteins (UCPs) are carriers that belong to the
protein superfamily constituted by the metabolite transporters
of the mitochondrial inner membrane. In mammals, five genes
encode proteins considered UCPs (Ledesma et al., 2002a;
Krauss et al., 2005). UCP1 is present in brown adipose tissue
(BAT), UCP2 is ubiquitous, and UCP3 is expressed in heart,
skeletal muscle, and brown adipose tissue. UCP4 and BMCP1
(UCP5) are predominantly expressed in the nervous system.
Genes homologous to the mammalian UCPs have been
described not only in most phyla of the animal kingdom but
also in plants and unicellular eukaryotes (Ledesma et al.,
2002a). The function of the different members of the UCP protein
family is not fully established. Their biological activity appears to
be linked to the modulation of the efficiency of the oxidative
phosphorylation, although the actual molecular mechanism
may vary among the different familymembers. This energy-dissi-
pating mechanism is used in functions as diverse as the elimina-
tion of an excess calorie intake, regulation of insulin secretion, or
maintenance of body temperature (Krauss et al., 2005). Because264 Chemistry & Biology 18, 264–274, February 25, 2011 ª2011 Elsethe UCPs presumably increase the rate of mitochondrial respira-
tion, an increase in their activity would also lead to a reduction in
the mitochondrial production of superoxide. In fact, UCPs are
up-regulated in many physiological situations where there is
oxidative stress, and there are data showing that their overex-
pression reduces ROS damage. As a consequence, UCPs are
widely considered as an additional element of antioxidant
defense (Brand and Esteves, 2005; Nu¨bel and Ricquier, 2006;
Echtay, 2007; Baffy, 2010). Although the acceleration of respira-
tion due to UCP-mediated uncoupling would lead to a reduction
in ROS production, it has also been proposed that UCPs could
induce a metabolic shift that would promote glycolysis and
therefore indirectly lower ROS production (Bouillaud, 2009).
Themitochondrial activity of the UCPs is regulated by different
ligands, although the physiological relevance of some of them is
unclear. Only the physiological regulation of the uncoupling
protein from BAT, UCP1, is well understood. Cytosolic purine
nucleotides inhibit UCP1, while fatty acids override the inhibition
and increase its proton conductance (Rial and Gonza´lez-
Barroso, 2001). This regulatory mechanism fits precisely with
its physiological context: noradrenaline binds to b-receptors,
initiating a cAMP-dependent lipolytic cascade where the fatty
acids liberated are the substrates that mitochondria will oxidize
and the activators of UCP1 (Rial and Gonza´lez-Barroso, 2001).
Although nucleotides and fatty acids are the more prominent
regulators, there are other ligands that modulate the proton
conductance in UCP1. Thus, all-trans-retinoic acid (ATRA) is
a high-affinity activator of the protein (Rial et al., 1999) and, inter-
estingly, also is a powerful transcriptional activator of the ucp1
gene (Alvarez et al., 1995). Additionally, reduced ubiquinone
lowers the affinity of UCP1 for nucleotides and, as a result, facil-
itates the activation by fatty acids (Swida-Barteczka et al., 2009).
Ubiquinone also increases the affinity of UCP1 for ATRA (Toma´s
et al., 2002).
The regulation of the rest of the members of the UCP family is
not yet understood (Brand and Esteves, 2005; Cannon et al.,
2006; Echtay, 2007; Azzu and Brand, 2010). The interpretation
of most data is complicated by the discovery that the adenine
nucleotide translocator (ANT) could be responsible for some of
the effects ascribed to the UCPs. Furthermore, the ANT has
been shown to contribute significantly to the basal proton
conductance (Brand et al., 2005). The inhibition of proton trans-
port by GDP has often been used as diagnostic for the involve-
ment of a UCP in the modulation of the efficiency of the oxidative
phosphorylation, but GDP, although not translocated by thevier Ltd All rights reserved
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et al., 2006). The involvement of the UCPs in the defense against
oxidative stress led to the investigation of possible regulators
that could be generated when ROS levels rise. Thus, superoxide
and lipid peroxidation products such as hydroxynonenal have
been proposed to activate the UCPs (Echtay et al., 2002,
2003). These peroxidation products would set off a negative
feedback mechanism by which the activation of the UCPs would
increase respiration, lower ROS production, and thereby protect
against oxidative stress. Although this hypothesis is very attrac-
tive, the activation by ROS-derived products has not been
confirmed by some laboratories, and, as previously stated, the
ANT could account for the ROS-induced changes in proton
conductance (Couplan et al., 2002; Shabalina et al., 2010).
The development of specific inhibitors of the UCPs would
greatly facilitate the investigation of their transport activity and
regulation. Here we describe the identification and synthesis of
a family of inhibitors of the uncoupling proteins. We demonstrate
that certain chromane derivatives inhibit the fatty acid–induced
proton conductance of UCP1 without affecting other compo-
nents of the oxidative phosphorylation (OXPHOS) system.
Furthermore, the chromane derivatives also inhibit UCP2 in yeast
mitochondria. Finally, we show that in HT-29 tumor cells, which
express UCP2, chromanes inhibit respiration and increase ROS
levels. Interestingly, the inhibitor lowers the viability of HT-29
cells, increasing the efficacy of antitumor drugs that cause
oxidative stress, such as arsenic trioxide or doxorubicin.
RESULTS AND DISCUSSION
Chromane Derivatives Inhibit the Uncoupling
Protein UCP1
All-trans retinoic acid (ATRA) up-regulates the expression of the
uncoupling proteins UCP1 and UCP2 (Alvarez et al., 1995; Hata-
keyama and Scarpace, 2001). We have previously shown that
ATRA also activates the proton conductance of UCP1 and
UCP2 (Rial et al., 1999). Because a large collection of
compounds structurally related to ATRA has been synthesized
as specific ligands for retinoid receptors (Altucci et al., 2007),
we screened a set of retinoids to get an insight into the specificity
of the UCP1 ligand (Toma´s et al., 2004). The screening protocol
was based on the analysis of the effect of the compounds on the
rate of NADH oxidation bymitochondria isolated from Saccharo-
myces cerevisiae that expressed UCP1 (Toma´s et al., 2004).
Under our experimental conditions, in the absence of added
regulators, yeastmitochondria expressingUCP1present a respi-
ratory activity higher than that of control mitochondria (Fig-
ure 1A). This higher respiration rate can be inhibited by purine
nucleotides and represents the basal proton conductance of
UCP1 (Gonza´lez-Barroso et al., 1998; Jime´nez-Jime´nez et al.,
2006).
Figure 1Ashows the effect of ATRA in controlmitochondria and
mitochondria containing UCP1. The low concentrations of ATRA
used only stimulate respiration (NADH oxidation) when UCP1 is
present. We have previously shown that the increase can be in-
hibited by GDP (Rial et al., 1999; Toma´s et al., 2004). We have
also described that other retinoids, which must possess a free
carboxylate group, are also activators of UCP1. Interestingly,
the retinoid AGN199108 displayed a nonspecific stimulationChemistry & Biology 18, 264of NADH oxidation in control mitochondria (Figure 1B), an
uncoupling effect that was also evident in UCP1-containing
mitochondria. However, at low concentrations, this retinoid
decreased the NADH oxidation rate in UCP1 mitochondria,
thus suggesting the inhibition of the basal proton conductance
of UCP1. The reason behind this mixed behavior could be the
ester hydrolysis under aqueous conditions that generates two
new organic acids, 2,2,4,4-tetramethylchroman-6-carboxylic
acid and (E)-3-(4-hydroxyphenyl)acrylic acid, from the starting
retinoid. Because small organic acids can permeate across the
lipid bilayer, the two resulting compounds could act as protono-
phores and thus explain the observed nonspecific uncoupling
activity.
Nucleotides inhibit UCP1 by binding deep inside the a-helical
bundle core with the purine ring interacting with the matrix loops
(Gonza´lez-Barroso et al., 1999; Ledesma et al., 2002b). The
chromane moiety of the retinoid AGN199108 could act as
a surrogate of the purine ring, and we thus hypothesized that
this moiety would be responsible for the inhibition. To test the
hypothesis, two chromane derivatives, 6-bromo-8-isopropyl-
2,2-dimethylchromane (CSIC-E183) and 8-isopropyl-2,2-dime-
thylchroman-6-carboxylic acid (CSIC-E137), were synthesized
and their activity tested. The chromane CSIC-E137 retained
the carboxylic moiety, whereas in the chromane CSIC-E183,
the position C-6 at the chromane ring was substituted by
a bromine to remove the protonable residue. Experiments with
control mitochondria confirmed the essential role of the carbox-
ylate for the protonophoric properties because the bromine-
substituted compound had no significant effect on respiration
(Figure 1C). The inhibitory properties of CSIC-E183 on UCP1
containing mitochondria were tested in the presence of
palmitate to include a physiological activator. Data clearly
demonstrate that CSIC-E183 was able to inhibit both the palmi-
tate-induced and the basal proton conductance of UCP1
because the rate of NADH oxidation was decreased to the level
of control mitochondria (Figure 1D).
Characterization of the Active Compounds
To determine the structural requirements of the inhibitory
compounds, we designed and synthesized a series of chromane
derivatives of general structure I, and some of them proved to be
valuable inhibitors of UCP1. In these derivatives, we analyzed the
effect of the substituents in four different positions (R1–R4) thus
allowing us to establish the first basis of their influence on the
inhibitory activity of these chromanes. Table 1 gathers the new
series of compounds examined and presents the data obtained
when tested in control yeast mitochondria and mitochondria
containing UCP1. The EC50 was calculated from the difference
in inhibition kinetics (see Figures S1 and S2 available online).
One of the most marked structural features for inhibition of
UCP1, which arises upon inspection of Table 1, is the crucial
presence of a substituent at C-8 of the chromane skeleton.
Thus, lower EC50 values are obtained when R
4 is an alkyl group
than when R4 is a proton (entries 1–9 vs. entries 12–15). Linear
and branched alkyl groups are well-tolerated at the C-8 position
increasing the potency of the inhibitors, mainly for the ethyl
group (entries 1–4); however, a methyl ketone at this position
precludes the inhibition (entry 10). We also evaluated the influ-
ence of the nature of the group R3. The presence of an acidic–274, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 265
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Figure 1. Chromane Derivatives Inhibit the Proton
Conductance of UCP1
The activity of UCP1 is determined from the rate of NADH
oxidation of mitochondria from yeast that express UCP1
recombinantly (filled circles) and compared with control
yeast mitochondria (empty circles). Rates of respiration
are expressed as a percentage of the maximal rate of
respiration that is determined in the presence of 1 mM
FCCP. Data are means ± SEM of 4–6 independent exper-
iments each performed in triplicate.
(A) Activation of respiration in UCP1 containing mitochon-
dria by ATRA and lack of effect on control mitochondria.
(B) Activation by the retinoid AGN-199108.
(C) Effect of the chromanes CSIC-E137 and CSIC-E183 on
control yeast mitochondria.
(D) Effect of the compound CSIC-E183 on control yeast
mitochondria and UCP1-containing yeast mitochondria.
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(EC50, >200 mM) that is recovered, however, upon esterification
(EC50, 27 mM) (entries 16 vs. 6). The absence of a substituent
(R3 = H) and the substitution by a bromine allow for moderate
inhibitory activities (entries 9 and 3). Alternatively, the introduc-
tion of an aromatic group (R3 = Ph) leads to the most potent
inhibitor in the series (entry 5); in contrast, a vinyl group in this
position hampers the inhibitory activity (entry 11). Finally, we
examined the nature of the substitution at the oxygenated ring,
and no significant differences have been found between the
chromane skeletons examined, 2,2-dialkylated and 4,4-dialky-
lated (R1 = Me vs. R2 = Me, entries 6/7 and 8/9); however, the
need for the chromane ring has been proven with the lack of inhi-
bition of CSIC-E243 (4-bromo-2-isopropyl-1-methoxybenzene),
a monocyclic analog to CSIC-E183 and CSIC-E179 (entries 17,
3, and 8). Consequently, the chromane with the highest affinity,266 Chemistry & Biology 18, 264–274, February 25, 2011 ª2011 Elsevier Ltd All rightsCSIC-E379 (8-isopropyl-2,2-dimethyl-6-phe-
nylchromane; EC50, 20 mM), was used as inhib-
itor for the remaining of the work. Similarly, the
chromane CSIC-E167 was subsequently used
as inactive control because of its lack of effect
on UCP1.
Chromane Derivatives Inhibit
the Uncoupling Protein UCP2
We have previously reported that, when the un-
coupling protein UCP2 is expressed recombi-
nantly in S. cerevisiae, the isolatedmitochondria
present a higher state 4, whereas the phosphor-
ylation rate or the maximal respiratory activity
remain unchanged (Rial et al., 1999). The effect
of the chromanes on UCP2 was also tested
using the NADH-based screening protocol.
Under these experimental conditions, UCP2-
containing mitochondria presented a higher
basal respiratory activity, although the differ-
ence with control mitochondria accounted for
only 9% of the maximal respiratory capacity
(Figure 2; Figure S3). The active chromane
CSIC-E379 caused the inhibition of the UCP2-
dependent respiratory activity that was evidentwhen the nonspecific effects on control mitochondria were taken
into account (Figure 2). The estimated EC50 was close to 30 mM
and thus similar to the one obtained with UCP1 (Table 1). As ex-
pected, when the UCP1-inactive compound CSIC-E167 was
tested on mitochondria containing UCP2, the NADH oxidation
rate was not modified (Figure 2; Figure S3).
Chromane Do Not Affect OXPHOS in Liver Mitochondria
The screening protocol used to characterize the inhibitory pro-
perties of the chromane derivatives is performed under nonphos-
phorylating conditions. Because we had hypothesized that the
inhibition of the proton transport activity of UCP1 by chromane
moiety was likely due to its resemblance with the purine ring, it
was necessary to assess whether the chromane derivatives were
interfering with the exchange of ADP/ATP or the phosphorylation
of ADP at the F0F1-ATPase. Figure 3 presents the effect of thereserved
Table 1. Chemical Structure, Nomenclature, and Activity of the Chromane Derivatives Synthesized and Characterized in the Present
Study
>2504-bromo-2-isopropyl-1-methoxybenzene (see text)CSIC-E24317
>200i-PrCO2HHMeCSIC-E13716
>200HCO2EtMeHCSIC-E111315
>200HBrHMeCSIC-E16714
109HPhHMeCSIC-E37513
135HCO2EtHMeCSIC-E112512
>200i-PrCH=CH2HMeCSIC-E39311
>200COCH3BrMeHCSIC-E16110
98i-PrHHMeCSIC-E1559
132i-PrBrMeHCSIC-E1798
32i-PrCO2EtMeHCSIC-E1131B7
27i-PrCO2EtHMeCSIC-E11276
20i-PrPhHMeCSIC-E3795
39t-BuBrHMeCSIC-E2314
111i-PrBrHMeCSIC-E1833
54PrBrHMeCSIC-E2212
34EtBrHMeCSIC-E2251
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4
The concentration that causes a 50% inhibition of transport activity of UCP1 (EC50) was calculated from the difference between the NADH oxidation
rates in UCP1-containing mitochondria and control mitochondria. Experimental data for each compound are included in Figures S1 and S2.
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Figure 3. Effect of the Chromane CSIC-E379 on the Oxidative Phos-
phorylation of Isolated Rat Liver Mitochondria
(A) Representative traces with the measurement of the oxygen consumption in
the presence and absence of the compound CSIC-E379. Respiration was initi-
ated with the addition of glutamate 5 mM plus malate 5 mM (G/M); the state 3
respiration rate was determined after the addition of ADP 0.2 mM. FCCP 1 mM
was added at the end of the run. Rates are expressed as nmol ‘‘O’’ per minute
and milligrams of protein.
(B) Effect of CSIC-E379 on the rate of respiration in the basal state 4 (filled bars)
and in state 3 (empty bars). Bars represent the mean ± SEM of 4–5 indepen-
dent experiments. There are no significance differences (n.s.) between the
rates in the presence and absence of the chromane.
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Figure 2. Chromane Derivatives Inhibit Respiration in UCP2-Con-
taining Yeast Mitochondria
Respiration was determined from the rate of NADH oxidation in control mito-
chondria and mitochondria isolated from yeasts expressing UCP2 recombi-
nantly, either in the presence of CSIC-E379 (circles) or CSIC-E167 (triangles).
Data are expressed as the difference in the NADH oxidation rate of UCP2
minus control mitochondria (see also Figure S3). Data points are means ±
SEM of 3 independent experiments each performed in triplicate.
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CSIC-E379 had no effect on the basal respiratory rate (state 4),
thus ruling out a direct effect on the respiratory complexes or the
membrane permeability. Although this chromane had no statisti-
cally significant effect on the phosphorylation of added ADP
(state 3), a trend is apparent showing a 10% inhibition when the
concentration was raised to 60 mM. Therefore, the chromane
CSIC-E379 does not significantly affect the OXPHOS system.
Chromane Derivatives Inhibit the Cellular Respiration
of the Cancer Cell Line HT-29
The biochemical activity of the UCPs is to lower the efficiency of
the oxidative phosphorylation, presumably by increasing the
membrane proton conductance. This mild uncoupling would
lead to an increase in respiration, which results in a lower gener-
ation of superoxide due to the decrease in proton-motive force.
This uncoupling effect could constitute a mechanism of defense
against oxidative stress. Indeed, UCPs are up-regulated in phys-
iological situations where there is oxidative stress and, further-
more, their overexpression reduces ROS damage (Echtay,
2007; Azzu and Brand, 2010; Baffy, 2010; Rial et al., 2010).
The effect of the chromane CSIC-E379 on the cellular respira-
tion was investigated using the cell line HT-29, a colon cancer
cell line that expresses the uncoupling protein UCP2 (Figure S4).
Cells were incubated for 1 hr in the presence of the chromane,
and then the respiratory activity was determined on an XF24
Extracellular Flux Analyzer. Figure 4A shows that the chromane
causes a 22% decrease in the basal rate of respiration, in agree-
ment with the data obtained with UCP2-containing yeast mito-
chondria. Genipin, an iridoid glucoside, has also been described
to inhibit UCP2. Genipin is extracted from the fruits of Gardenia
jasminoides and is used in traditional Chinese medicine to treat,268 Chemistry & Biology 18, 264–274, February 25, 2011 ª2011 Elseamong other diseases, type 2 diabetes. Zhang et al. (2006) re-
ported that genipin inhibited UCP2 in b-cells, raising ATP levels
and increasing insulin secretion while reducing insulin-stimu-
lated glucose uptake in 3T3-L1 adipocytes (Zhou et al., 2009).
Mailloux et al. (2010) have recently reported that genipin also
inhibits respiration in UCP2 overexpressing leukemia cells.
Bouillaud (2009) has proposed a ‘‘metabolic hypothesis,’’
whereby UCP2 (and UCP3) has a transport activity that does
not involve proton translocation. The working model proposesvier Ltd All rights reserved
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Figure 4. The chromane CSIC-E379 inhibits mito-
chondrial respiration in HT-29 colon cancer cells
causing oxidative stress and decreasing their
viability
(A) Basal rate of oxygen consumption of HT-29 cells after
subtraction of the rate obtained in the presence of antimy-
cin A and rotenone. Cells were incubated for 1 hr in the
presence (empty bar) or in the absence (filled bar) of
20 mMCSIC-E379. Data are themean ± SEM of three inde-
pendent experiments.
(B) Representative flow-cytometry histograms of the ROS
levels determined with the fluorescent probe H2DCFDA in
control HT-29 cells (left panel) or cells treated for 24 hr with
CSIC-E379.
(C) Histograms summarizing the effect of the chromanes
CSIC-E379 and CSIC-E167 on ROS levels in HT-29 cells
after a treatment for 24 hr. Treatment with the respiration
inhibitor rotenone for 1 hr is used as positive control for
ROS generation. Bars represent the mean ± SEM of 5-6
independent experiments.
(D) Effect of the compound CSIC-E379 on the viability of
HT-29 cells after a 24 hr treatment determined from the
rate of reduction of the reagent WST-1. Data points repre-
sent the mean ± SEM of 8–10 independent experiments
each performed in triplicate.
See also Figure S4.
Chemistry & Biology
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matrix, thus limiting substrate supply to mitochondria, and that
would also lead to a metabolic shift that would promote glycol-
ysis. The lower redox pressure on the mitochondrial respiratory
chain would indirectly lead to a decreased ROS production.
The observed effects of genipin or the chromane derivatives
would not be compatible with this hypothetical transport activity
because thepredicted effect of the inhibition ofUCP2would have
been a higher (or an unchanged) rate of respiration. The inconsis-
tency is even more evident when the effect of the chromanes on
UCP2-containing yeastmitochondria is taken into consideration.
Chromane Derivatives Increase the Production
of Superoxide and Decrease the Viability
of the Cancer Cell Line HT-29
Compared with their nontransformed counterparts, cancer cells
often present high intrinsic oxidative stress, which is probablyChemistry & Biology 18, 264–274, February 25a determinant for oncogenic transformation
(Trachootham et al., 2009). Cells adapt to
increased ROS levels with defense mechanisms
that include the up-regulation of antioxidant
enzymes (superoxide dismutase, catalase, and
glutathione peroxidase) and enzymes that
regenerate nonenzymatic antioxidants, such
as gluthatione reductase or the thioredoxin
system. In addition, tumor cells defend them-
selves against the deleterious effects of oxida-
tive stress by promoting the expression of cell-
survival proteins, such as Bcl-2, or by activating
survival pathways such as PI3K/Akt or MEK/
ERK (Trachootham et al., 2009; Pani et al.,
2010). In this regard, UCP2 has been shown to
be expressed in cancer cells (Carretero et al.,1998; Harper et al., 2002; Horimoto et al., 2004; Samudio
et al., 2008; Santandreu et al., 2009, 2010; Mailloux et al.,
2010; Sastre-Serra et al., 2010; Baffy, 2010), and it has been
proposed that UCP2 could be a metabolic strategy used by
the tumor cells to develop resistance against radio- or chemo-
therapy (Harper et al., 2002; Mailloux et al., 2010; Baffy, 2010).
The capacity of the chromane derivatives to inhibit UCP2 and
influence cell viability was first tested by analyzing their effect on
ROS levels in HT-29 cells. Figure 4B presents representative
histograms of ROS levels determined with fluorescent probe
H2DCFDA in control cells and cells treated for 24 hr with the
chromane CSIC-E379. Data show that the active chromane
CSIC-E379 causes an increase in ROS levels, similar to that
obtained with rotenone, which is not evoked by the inactive
compound CSIC-E167 used as a control (Figure 4C). The
observed chromane-induced increase in ROS resembles those
reported when tumor cells are treated with genipin (Mailloux, 2011 ª2011 Elsevier Ltd All rights reserved 269
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Figure 5. The compound CSIC-E379 sensi-
tizes the cancer cell line HT-29 to arsenic
trioxide
(A) Titration of the effect of ATO on the viability of
the cells treated for 24 hr in the absence (filled
circles) or in the presence of 20 mM CSIC-E379
(empty circles).
(B) Effect of ATO on the viability of the cells treated
for 48 hr in the absence of chromanes (filled
circles), in the presence of 20 mM CSIC-E379
(empty circles), or in the presence of 20 mM
CSIC-E167 (gray diamonds). In panels (A) and
(B), data points represent the mean ± SEM of
8–16 independent experiments each performed
in triplicate. Difference between control values
and those from CSIC-E379 treated cells are signif-
icant, with p < 0.001.
(C) Representative flow cytometry profiles of the
effect of ATO and CSIC-E379 on HT-29 cells. Cells
were treated for 24 hr, stained with Annexin-V and
PI, and apoptosis subsequently was analyzed by
flow cytometry. Left panel, control cells; central
panel, cells treated with 10 mM ATO; right panel,
cells treated with 10 mM ATO plus 20 mM CSIC-
E379.
(D) Histogram summarizing the analysis of the
effect of the chromane derivatives CSIC-E379
and CSIC-E167 on the apoptosis of HT-29 cells.
Empty bars represent the viable cells and are
those that are not stained with Annexin-V or PI;
hatched bars represent the cells in the early
apoptotic phase that are Annexin-V positive and
PI negative; and black bars represent the cells in
late apoptosis plus necrotic cells and therefore
include all PI positive cells. Bars represent the
mean ± SEM of 3–8 independent experiments
each performed in duplicate.
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overexpression of UCP2 in the colon cancer cell line HCT116 has
been shown to decrease the ROS levels (Derdak et al., 2008).
The intrinsic elevated level of oxidative stress makes tumor
cells more susceptible to the action of ROS-inducing cytotoxic
agents, a property that has been satisfactorily exploited in anti-
tumor therapies (Lau et al., 2008; Trachootham et al., 2009).
We therefore tested the effect of the chromane CSIC-E379 on
the cell viability and observed that the concentration (20 mM)
and treatment time (24 hr) that were shown to increase the
ROS level caused a moderate, although significant, decrease
in viability (Figure 4D). When the concentration of CSIC-E379
was raised to 50 mM, the decrease in viability was close to
50%. Again, genipin has also been shown to reduce the viability
of other tumor cells lines that express UCP2 (Mailloux et al.,
2010; Santandreu et al., 2010).270 Chemistry & Biology 18, 264–274, February 25, 2011 ª2011 Elsevier Ltd All rights reservChromane Derivatives Potentiate
the Efficacy of the Cytotoxic Drug
Arsenic Trioxide
As indicated above, the elevated intrinsic
oxidative stress of tumor cells is behind
the efficacy of therapies with some anti-
tumor drugs or radiation. The increase in
oxidative stress can be due to a directgeneration of ROS and/or to an interference with the antioxidant
defenses. Arsenical compounds, such as arsenic trioxide (ATO),
have been shown to be effective in the treatment of acute pro-
myelocytic leukemia and other human cancers (Lau et al.,
2008). Generation of ROS is one of the mechanisms explaining
the induction of apoptosis by ATO. Interestingly, the ATO effi-
cacy is determined, at least in part, by the intracellular redox
status. Thus, it is known that its cytotoxicity is greatly dependent
on the intracellular content of reduced glutathione and that, for
example, depletion of glutathione stores sensitizes cells to
ATO (Yi et al., 2002; Lau et al., 2008). In the same context, we
have recently shown that genistein, a soy-derived isoflavone,
behaves as a pro-oxidant agent potentiating ATO-induced
apoptosis in human leukemia cells via ROS overproduction
and the activation of the ROS-inducible protein kinases p38-
MAPK and AMPK (Sa´nchez et al., 2008).ed
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Figure 6. The chromane derivative CSIC-
E379 sensitizes HT-29 cancer cells to doxo-
rubicin and cisplatin
Cell viability was determined from the reduction of
WST-1. In the two panels, data points represent
the mean ± SEM of at least 9 independent experi-
ments each performed in triplicate. The difference
between the control values and those from CSIC-
E379 treated cells are significant, with p < 0.001.
(A) Effect of doxorubicin on the viability of the cells
treated for 48 hr in the absence (filled circles) or in
the presence of 20 mM CSIC-E379 (empty circles).
(B) Effect of CDDP on the viability of the cells
treated for 48 hr in the absence (filled circles) or
in the presence of 20 mM CSIC-E379 (empty
circles).
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increases ROS levels in the cancer cell line HT-29, it was of
interest to determine whether its combination with ATO could
also potentiate the effect of the antitumor drug. Figure 5A pres-
ents the effect of increasing ATO concentrations on the viability
of HT-29 cells incubated for 24 hr either in the absence or in the
presence of 20 mMCSIC-E379. Data revealed that the decreased
in viability was markedly pronounced in the presence of the
UCP2 inhibitor but the effect appeared as additive. However,
when the treatments were maintained for 48 hr (Figure 5B), the
ATO toxicity was clearly potentiated, being more evident at
very low doses. Thus, 5 mM ATO (concentration close to the
useful therapeutic dose) caused a 10% reduction in viability,
whereas in the presence of CSIC-E379, the reduction was close
to 35%. As expected, the inactive chromane CSIC-E167 had no
potentiating effect.
The cell viability is often inferred from themetabolic activity and,
thus, we used a protocol based on the reduction of the reagent
WST-1 that is dependent on the rate of NAD(P)H formation. To
ascertain the effect of the chromanes on cell death, we analyzed
the cellular apoptosis and necrosis using annexin-V labeling
combined with propidium iodide (PI) staining. Figure 5D summa-
rizes the results that revealed that, as expected, 10 mM ATO
decreases the number of viable cells and causes a marked
increase inannexin-V–positivecells that representcells in theearly
apoptotic phase. When the inhibitor was present, the reduction in
viable cells was not significantly different, but the number of
PI-positive cells (late apoptotic or necrotic cells) was greatly
increased. It appears that UCP2 inhibition exacerbates cell death.
The potentiating effect of the chromane CSC-E379 was also
testedwith theantitumordrugscisplatin (CDDP)anddoxorubicin.
The twodrugs are known to induce oxidative stress, andprevious
studies have shown that UCP2 could influence their toxicity (Der-
dak et al., 2008; Mailloux et al., 2010; Santandreu et al., 2010).
Figure 6 presents the effect of CSIC-E379 on the viability after
the treatment for 48 hr with varying concentrations of the two
drugs. The inhibitor cooperates in more than additive manner
with the two agents, thus confirming that UCP2 inhibition sensi-
tizes cancer cells to agents commonly used in chemotherapy.
Conclusion
The 3D-structure of theUCPs is not available, but the structure of
the ANT has revealed the common structural scaffold of theChemistry & Biology 18, 264mitochondrial carriers (Nury et al., 2006). The basic fold is a barrel
formed by the six transmembrane a helices that is closed at the
matrix side. The a helices define a hydrophilic cavity opened to
the intermembrane space and that enters deeply into the protein,
constituting the translocation pathway. The nucleotide-binding
site in UCP1 is probably the best-known structural feature of
the protein. Photoaffinity labeling and site-directed mutagenesis
experiments have shown that the nucleotide enters the protein
through its cytosolic side and gets deep inside the cavity to
interact with the loops at the bottom of the barrel. We have
proposed that the purine ring would fit in a hydrophobic pocket
and that its stabilization would occur through stacking interac-
tions, as it happens in other nucleotide binding proteins (Gonza´-
lez-Barroso et al., 1999; Ledesma et al., 2002b). The hydropho-
bicity and planar structure of the chromane derivatives identified
in the present report suggest that the chromane could probably
occupy the same site than the purine ring.
As we have previously stated, GDP inhibition of the mito-
chondrial proton conductance was considered for many
years as diagnostic of the involvement of a UCP. However, it
has become clear that the activity of the ANT, being the most
abundant carrier, overlaps with that of the UCPs and can also
be inhibited by GDP. As a result, doubts have been shaded
on some biological activities attributed to the UCPs. The
discovery that the effect of genipin in b-cells is mediated by
UCP2 has led to its use as a ‘‘specific’’ UCP2 inhibitor.
However, genipin is a natural product used in traditional
Chinese medicine to treat a variety of diseases. Thus, it exhibits
anti-inflammatory and anti-angiogenic activities, inhibits lipid
peroxidation, and suppresses cell proliferation and migration
(Koo et al., 2004; Yamazaki and Chiba, 2008; Kim et al.,
2010). Recent studies have also reported that genipin protects
against D-galactosamine/lipopolysaccharide-induced hepatic
apoptosis and liver failure by preventing oxidative stress,
apoptosis, NF-kB nuclear translocation, and nuclear c-Jun
expression (Kim et al., 2010). Finally, it should be borne in
mind that genipin is a highly reactive nonspecific cross-linking
agent that, for example, is used to generate biocompatible
polymers (Slusarewicz et al., 2010). Therefore, the possible
side effects imply that caution should be exerted when using
genipin as a ‘‘specific’’ UCP2 inhibitor. The above facts
evidence the need for new and selective inhibitors of the uncou-
pling proteins. Further optimization of the chromane derivatives–274, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 271
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affinity inhibitors. Data presented point to their application as
tools for uncoupling protein research and even as new chemo-
therapeutic agents.
SIGNIFICANCE
Mitochondria play a key role in cellular processes that range
from energy production to redox or calcium homeostasis,
participating in a wide range of metabolic pathways. How-
ever, although mitochondria are essential for cell survival,
a variety of death signals converge on mitochondria making
this organelle also central to cell death. Mitochondria are
also oneof themain sites ofROSproduction, and thusmech-
anisms that prevent ROS damage are not only critical for the
preservation of their function but also for cell survival. The
uncoupling proteins (UCPs) control the energetic efficiency,
and one of the consequences is that they participate in the
control of mitochondrial ROS production.
The search for new regulators of the uncoupling activity of
UCP1 has led to the discovery of a small-molecule inhibitor
of the UCPs that we have presented. UCP2 appears as one
of the most interesting pharmacological targets of the chro-
mane derivatives, and, thus, we have explored the applica-
tion of the inhibitor to increase oxidative stress in tumor
cells with the aim of generating an imbalance in ROS status
and thus make the cells more susceptible to other chemo-
therapeutic drugs. The use of selective combinations of
drugs to enhance their therapeutic efficacy is a common
approach undertaken in cancer treatment. Because UCP2
appears to be linked to the antioxidant defense of tumor
cells and has even been shown to promote chemoresistance
(Harper et al., 2002; Derdak et al., 2008; Mailloux et al., 2010;
Baffy, 2010), the development of small-molecule UCP2 inhib-
itors is a promising new step in the development of novel
anticancer strategies.
EXPERIMENTAL PROCEDURES
Synthesis of Chromane Derivatives
The syntheses of 4-bromo-2-isopropyl-1-methoxybenzene (Burnel and
Caron, 1992), 6-bromo-2,2-dimethylchromane (Bernard et al., 1998), ethyl
2,2-dimethylchroman-6-carboxylate (Teng et al., 1997), and 6-phenyl-2,2-di-
methylchromane (Ishino et al., 2001) were previously reported. 2,2-Dimethyl
chromanes were prepared by cyclization of phenols with 3-methyl-2-buten-
1-ol (Ishino et al., 2001). 4,4-Dimethyl chromanes were prepared by
a sequence that entails O-alkylation of phenols with 4-bromo-2-methyl-2-
butene, acetoxymercuriation/reduction, and cyclization mediated by AlCl3
(Janusz et al., 1998). 6-Phenyl and 6-vinyl chromanes were prepared by
a Stille coupling from 6-bromo chromanes and vinyl or phenyl tributylstan-
nanes (McKean et al., 1987). 6-Carboxyethyl chromanes were obtained
from 6-bromo chromanes with t-BuLi and ethyl chloroformate. Further
saponification with NaOH yielded the carboxylic acid. Finally, 8-acetyl chro-
mane was prepared from the chromane via Friedel-Crafts acylation with
acetyl chloride and AlCl3. All the compounds were purified and characterized
prior to submission to biological essays (see details in Supplemental Exper-
imental Procedures).
Yeast Strains, Isolation of Yeast Mitochondria, and Determination
of Mitochondrial NADH Oxidation
The procedures for recombinant expression of the rat uncoupling protein
UCP1 or the mouse UCP2 in the S. cerevisiae strain W303 and the protocol272 Chemistry & Biology 18, 264–274, February 25, 2011 ª2011 Elsefor the isolation of mitochondria from yeasts have been described previously
(Arechaga et al., 1993). The control strain contained the same vector but
with the UCP1 cDNA in the inverse orientation.
The rate of yeast mitochondrial respiration was determined from the
decrease in NADH fluorescence as previously described (Toma´s et al.,
2004). Mitochondria (0.1 mg protein/ml) were incubated at 20C in medium
containing 0.65 M mannitol, 0.5 mM EGTA, 10 mM phosphate, 2 mM MgCl2,
3 mM essentially fatty-acid-free albumin, and 10 mM Tris/maleate (pH 6.8).
When required, the medium also contained 9 mM palmitate (3:1 molar ratio
to albumin). Respiration was initiated by the addition of 0.3 mM NADH. Exper-
iments were performed on standard 96-well microtiter plates, and fluores-
cence was measured in a POLARstar Galaxy reader (BMG Labtechnologies).
Excitation was set at 340 nm and emission at 470 nm.
Isolation of Liver Mitochondria and Determination
of Respiration Rates
Mitochondria from rat liver were isolated as previously described (Heaton and
Nicholls, 1976). Final pellet was resuspended in a buffer containing 250 mM
sucrose, 5 mg/ml albumin, and 10 mM Tes (pH 7.4). Protein concentration
was determined by the BCAmethod. The respiration experiments were carried
out at 25C in a Hansa-Tech oxygen electrode. Mitochondria (0.5 mg/ml) were
suspended in medium containing 75 mM NaCl, 10 mM Tes, 1 mM EGTA,
1 mg/ml albumin, and 2 mM sodium phosphate (pH 7.0). Substrate was
5 mM glutamate plus 5 mM malate.
Cell Line and Measurements of Cellular Respiration
HT-29 colon carcinoma cells were obtained from the American Type Culture
Collection. Cells were cultured at 37C in a humidified 5% CO2 atmosphere
in DMEM (GIBCO) supplemented with 10% heat-inactivated FBS (Sigma),
2 mM L-glutamine, and 100 U/ml of penicillin/streptomycin (Invitrogen).
An XF24 Seahorse Bioscience instrument was used to measure the rate of
oxygen consumption of HT-29 cells; 60,000 cells per well were seeded in
XF24 cell culture plates in complete DMEM growth media and incubated at
37C, 5% CO2 for 24 hr prior to beginning the assay. For the XF24 assay,
DMEM growth media was replaced by unbuffered DMEM supplemented
with 25 mM glucose, 1 mM pyruvate, 2 mM L-glutamine, and 20 mM CSIC-
E379when indicated, and cells were incubated at 37C in a CO2-free incubator
for 1 hr. Cells were then placed in the instrument, and basal oxygen consump-
tion was recorded for 24 min. At the end of the run, 1 mM rotenone and 1 mM
antimycin A were added to determine the mitochondria-independent oxygen
consumption. Cells were lysed in 50 mM Tris, 150 mM NaCl, 2 mM EDTA,
1%NP40, 0.1% SDS, and 1% deoxycholate (pH 7.5), and the protein concen-
tration was determined with the BCA method.
Cell Viability and Apoptosis Assays
Cell viability was evaluated with the Cell Proliferation Reagent WST-1 (Roche
Diagnostics GmbH, Mannheim, Germany) following the manufacturer’s
instructions. For cell viability assays, 7000 cells were plated in 96-well plates
and grown for 24 or 48 hr in the absence of serum and in the presence of
the drugs. Ten microliters of WST-1 reagent was added to each well, cells
were incubated for 4 hr, and the dye absorbance at 480 nm was measured
using a Varioskan Flash (Thermo Fisher Scientific) plate reader. The absor-
bance at 690 nm was used as background.
Apoptosis was measured using Annexin-V and PI staining using the Vybrant
Apoptosis Assay Kit (Invitrogen) and following the manufacturer’s instructions;
300,000 cells were plated in 6-well plates and exposed to the different agents
in absence of serum for 48 hr. Floating and adherent cells were collected and
stained for 15 min at room temperature in the dark and were fluorescence
analyzed using an EPICS XL flow cytometer.
Measurement of ROS
ROS levels were determined by incubating the cells with 20,70-dichloro-dihy-
dro-fluorescein diacetate (H2-DCFDA, Molecular Probes). A total of 300,000
cells were plated in 6-well plates and exposed to the different agents in
absence of serum for 24 hr. Cells were incubated in the presence of 5 mM
H2-DCFDA for 1 hr at 37
C and a humidified 5% CO2 atmosphere in the
dark. Floating and adherent cells were harvested in the same medium, andvier Ltd All rights reserved
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treated for 1 hr with 10 mM rotenone were used as control.
Statistical Analysis
All values are expressed as mean ± SEM of at least three independent exper-
iments performed in triplicate. Differences between groups were determined
using either two-tailed unpaired Student’s t tests or the one-way ANOVA
test using the SigmaPlot software. Significant differences between groups
are indicated as *p < 0.05, **p < 0.01, and ***p < 0.001.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/j.
chembiol.2010.12.012.
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